Give 15% off, earn 10% back on every order they place.
Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
Delivers to EU in 3-7 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
Free shipping on orders over €200
Research-grade Triptorelin Acetate. 99.4% avg purity, HPLC & MS verified. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €29.99 | €29.99 | -- |
| 3+ | €28.49 | €85.47 | 5% off |
| 5+Most Popular | €26.99 | €134.95 | 10% off |
| 10+ | €25.49 | €254.92 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
99.4% average HPLC purity across our published lab reports
Janoshik report published when available
24h dispatch, EU-wide shipping from €4.99
Supplier batch specification on every product; independent Janoshik report on selected lots
Triptorelin is a GnRH agonist analogue -- a synthetic decapeptide with modifications at positions 6 and 10 of the native GnRH sequence that dramatically increase potency and half-life compared to endogenous GnRH. It is FDA- and EMA-approved for prostate cancer, endometriosis, and central precocious puberty under various brand names. Like all long-acting GnRH agonists, it produces an initial "flare" of LH and FSH (and consequently sex steroids) followed by receptor desensitization and profound gonadotropin suppression -- reducing circulating testosterone in men to castrate levels. Each vial contains 2mg.
The mechanism of action is counterintuitive until the receptor biology is understood. GnRH receptors respond to pulsatile stimulation; continuous high-level agonism from a long-acting analogue causes receptor downregulation and uncoupling from intracellular signaling. After 2-4 weeks of continuous exposure, LH and FSH secretion drops dramatically, and consequently so do testosterone and estradiol. This chemical castration is medically equivalent to surgical castration for testosterone-sensitive conditions.
For research applications, triptorelin is used to study GnRH receptor pharmacology, model hypogonadism (chemical castration models), investigate hormone-sensitive tissue biology in the absence of sex steroids, and as a positive control for GnRH agonist effects. The initial flare followed by suppression pattern also makes it useful for timing-controlled endocrine studies.
| Parameter | Value |
|---|---|
| Compound | Triptorelin acetate (GnRH agonist analogue) |
| Amount per Vial | 2mg |
| Purity | 99.4% avg (HPLC verified) |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or saline |
| Storage | -20°C; 2-8°C after reconstitution |
Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution and use within 14 days. Protect from light.
This is the paradox of GnRH agonist pharmacology. The pituitary GnRH receptor requires pulsatile stimulation to maintain LH and FSH secretion. When triptorelin provides continuous (rather than pulsatile) stimulation due to its long half-life, GnRH receptors become desensitized -- they downregulate and uncouple from signaling. After 2-4 weeks, LH and FSH secretion drops to very low levels, testosterone follows, and the result is chemical castration. The initial "flare" (a brief period of increased LH/FSH/testosterone before desensitization) is clinically important in prostate cancer because it can temporarily worsen symptoms before suppression begins.
In animal research, triptorelin (or other long-acting GnRH agonists) administered at sufficient doses produces reliable hypogonadism -- very low testosterone -- without surgical castration. This "chemical castration" model is useful for studying androgen-dependent processes, testing testosterone replacement or alternative therapies, and investigating testosterone's role in specific physiological systems. After cessation of triptorelin treatment, endogenous testosterone production recovers (unlike surgical castration), making chemical castration models reversible -- useful for before/after study designs.
All three are GnRH agonist analogues with the same fundamental mechanism of GnRH receptor desensitization and gonadotropin suppression. They differ primarily in modification sites, formulation, and half-life. Triptorelin is available as short-acting (daily injection) and long-acting (monthly/3-monthly depot) formulations. Leuprolide is similar with multiple depot options. Goserelin is formulated exclusively as a subcutaneous implant. For research, the short-acting daily-injection form of triptorelin or leuprolide allows better dose control than depot formulations, where the release kinetics add variability.
Triptorelin is supplied for laboratory research use only. Not approved for general human use outside of licensed therapeutic indications. Handle in compliance with institutional biosafety guidelines.
Triptorelin is a GnRH agonist analogue -- a synthetic decapeptide with modifications at positions 6 and 10 of the native GnRH sequence that dramatically increase potency and half-life compared to endogenous GnRH. It is FDA- and EMA-approved for prostate cancer, endometriosis, and central precocious puberty under various brand names. Like all long-acting GnRH agonists, it produces an initial "flare" of LH and FSH (and consequently sex steroids) followed by receptor desensitization and profound gonadotropin suppression -- reducing circulating testosterone in men to castrate levels. Each vial contains 2mg.
The mechanism of action is counterintuitive until the receptor biology is understood. GnRH receptors respond to pulsatile stimulation; continuous high-level agonism from a long-acting analogue causes receptor downregulation and uncoupling from intracellular signaling. After 2-4 weeks of continuous exposure, LH and FSH secretion drops dramatically, and consequently so do testosterone and estradiol. This chemical castration is medically equivalent to surgical castration for testosterone-sensitive conditions.
For research applications, triptorelin is used to study GnRH receptor pharmacology, model hypogonadism (chemical castration models), investigate hormone-sensitive tissue biology in the absence of sex steroids, and as a positive control for GnRH agonist effects. The initial flare followed by suppression pattern also makes it useful for timing-controlled endocrine studies.
| Parameter | Value |
|---|---|
| Compound | Triptorelin acetate (GnRH agonist analogue) |
| Amount per Vial | 2mg |
| Purity | 99.4% avg (HPLC verified) |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or saline |
| Storage | -20°C; 2-8°C after reconstitution |
Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution and use within 14 days. Protect from light.
This is the paradox of GnRH agonist pharmacology. The pituitary GnRH receptor requires pulsatile stimulation to maintain LH and FSH secretion. When triptorelin provides continuous (rather than pulsatile) stimulation due to its long half-life, GnRH receptors become desensitized -- they downregulate and uncouple from signaling. After 2-4 weeks, LH and FSH secretion drops to very low levels, testosterone follows, and the result is chemical castration. The initial "flare" (a brief period of increased LH/FSH/testosterone before desensitization) is clinically important in prostate cancer because it can temporarily worsen symptoms before suppression begins.
In animal research, triptorelin (or other long-acting GnRH agonists) administered at sufficient doses produces reliable hypogonadism -- very low testosterone -- without surgical castration. This "chemical castration" model is useful for studying androgen-dependent processes, testing testosterone replacement or alternative therapies, and investigating testosterone's role in specific physiological systems. After cessation of triptorelin treatment, endogenous testosterone production recovers (unlike surgical castration), making chemical castration models reversible -- useful for before/after study designs.
All three are GnRH agonist analogues with the same fundamental mechanism of GnRH receptor desensitization and gonadotropin suppression. They differ primarily in modification sites, formulation, and half-life. Triptorelin is available as short-acting (daily injection) and long-acting (monthly/3-monthly depot) formulations. Leuprolide is similar with multiple depot options. Goserelin is formulated exclusively as a subcutaneous implant. For research, the short-acting daily-injection form of triptorelin or leuprolide allows better dose control than depot formulations, where the release kinetics add variability.
Triptorelin is supplied for laboratory research use only. Not approved for general human use outside of licensed therapeutic indications. Handle in compliance with institutional biosafety guidelines.
Researcher Confidence
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Iceland, Israel, Serbia). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.